Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Knight Therapeutics Inc T.GUD

Alternate Symbol(s):  KHTRF

Healthcare
Knight Therapeutics Inc. is a specialty pharmaceutical company. The Company’s principal business activity is developing, acquiring, in-licensing, out-licensing, manufacturing, marketing and distributing pharmaceutical products in Canada, Latin America and select international markets. It finances other life sciences companies and secures product distribution rights for Canada and select international markets. The Company invests in life sciences venture capital funds whereby the Company may receive preferential access to healthcare products for Canada and select international markets. It develops pharmaceutical products, including those to treat neglected tropical and rare pediatric diseases. The portfolio consists of pharmaceutical products with molecules and includes both in-licensed products such as Lenvima, Cresemba, Halaven, Trelstar, Akynzeo, Ambisome, Minjuvi, Imvexxy as well as products owned by Knight such as Exelon and Impavido.


TSX:GUD - Post by User

Knight Therapeutics Inc
Bullboard Posts
User Avatar Image
(29)
•••
Comment by mjn797979on Jul 24, 2020 6:13pm
42 Views
Post# 31317137

RE:RE:RE:RE:RE:RE:RE:RE:RE:Benedict ...

RE:RE:RE:RE:RE:RE:RE:RE:RE:Benedict ...I agree totally.
Add this the covid crisis in Brazil, the REAL performance.

Its a foreign market to Canadian investors, I think it is key for them to inform us to the best of their abilities.
I would hope so anyways.

I don't think some of us are asking for much.
I will speak for myself, as a long time investor in this company, its the least of things to do.
I try to do my research and have listened to the earnings calls, I want more as an investor.

Some might say I am wrong in expecting this but I feel, having owned shares in other companies, Knight needs to improve their investors relations. I don't need a press release every week, just some updates here and there.

My 2 cents.
Bullboard Posts
Dealroom for high-potential pre-IPO opportunities